Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Fujifilm Receives Avigan Supply Requests from Overseas amid Coronavirus Outbreak
Fujifilm Holdings has received requests from several countries for exporting its anti-flu drug Avigan (favipiravir) for the treatment of novel coronavirus disease (COVID-19), its group company Fujifilm Toyama Chemical told Jiho on February 26. Although there have been media reports…
To read the full story
Related Article
- Kato Repeats May-End Goal for Avigan OK, Negative for Use in Mildly Ill Patients
May 11, 2020
- Japan Eyes May Approval for Avigan with Investigator-Led Study Data
May 7, 2020
- Japan Can’t Give “Special Approval” for Avigan under Current Law: Abe
April 30, 2020
- Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
- Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
- PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
- Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
BUSINESS
- BeiGene Sees Better-than-Expected Uptake for Brukinsa after March Launch
April 23, 2025
- CSL to Join Forces with Specialists to Raise Awareness of HAE: Japan President
April 23, 2025
- Takeda’s Japan Earnings Bottomed Out, Now on Pace to Growth from FY2025: Head
April 23, 2025
- Fujifilm CDMO Strikes US$3 Billion Manufacturing Deal with Regeneron
April 23, 2025
- Vital-Net Bags Japan Rights to Shield’s Iron Deficiency Med
April 23, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…